The administration says it's shifting responsibility for spending on anti-drug programs to the Departments of Justice and Health and Human Services — and away from the White House office — so it can better focus on policy.
This represents a 95 percent decrease in ONDCP's budget in just one year.
According to the new budget, the White House “drug czar’s” office is “charged with developing policies, objectives, and priorities for the National Drug Control Program.”
While the official budget recommends investing “$5 billion in new resources for the Department of Health and Human Services (HHS) over the next five years, including $1 billion in 2019, to combat the opioid epidemic,” the budget appendix also recommends redirecting the ONDCP’s two main grant programs, the High Intensity Drug Trafficking Areas (HIDTA) grant and the Drug Free Communities (DFC) Act, to the Departments of Justice and Health and Human Services.
Despite this recommended funding, the proposed $68.4 billion budget for HHS is a 21 percent decrease from the previous fiscal year.
Defending the move, the White House says “This proposal will enable ONDCP to focus resources on its core mission: to reduce drug use and its consequences by leading and coordinating the development, implementation, and assessment of U.S. drug policy.”
"DOJ and HHS are both major grant management organizations that can look holistically at allocations across law enforcement and drug prevention and treatment resources,” she added.
Over the last year, the ONDCP has been operating without a permanent director. Richard Baum has served as acting director since March 2017. On Feb. 9, the president nominated Jim Carroll, who serves as Assistant to the President and Deputy Chief of Staff to John Kelly, to head the agency.
Despite the sharp cuts to the drug control office's budget, White House press secretary Sarah Sanders said in a statement last week, “We have full confidence in Jim to lead ONDCP to make significant strides in combating the opioid crisis, reducing drug use, and coordinating U.S. drug policy.”